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severe aortic valve stenosis. It is unknown whether TAVR can be safely introduced to lower-risk patients.
OBJECTIVES The NOTION (Nordic Aortic Valve Intervention Trial) randomized clinical trial compared TAVR with sur-
gical aortic valve replacement (SAVR) in an all-comers patient cohort.
METHODS Patients $70 years old with severe aortic valve stenosis and no signiﬁcant coronary artery disease were
randomized 1:1 to TAVR using a self-expanding bioprosthesis versus SAVR. The primary outcome was the composite rate
of death from any cause, stroke, or myocardial infarction (MI) at 1 year.
RESULTS A total of 280 patients were randomized at 3 Nordic centers. Mean age was 79.1 years, and 81.8% were
considered low-risk patients. In the intention-to-treat population, no signiﬁcant difference in the primary endpoint was
found (13.1% vs. 16.3%; p ¼ 0.43 for superiority). The result did not change in the as-treated population. No difference in
the rate of cardiovascular death or prosthesis reintervention was found. Compared with SAVR-treated patients, TAVR-
treated patients had more conduction abnormalities requiring pacemaker implantation, larger improvement in effective
oriﬁce area, more total aortic valve regurgitation, and higher New York Heart Association functional class at 1 year. SAVR-
treated patients had more major or life-threatening bleeding, cardiogenic shock, acute kidney injury (stage II or III), and
new-onset or worsening atrial ﬁbrillation at 30 days than did TAVR-treated patients.
CONCLUSIONS In the NOTION trial, no signiﬁcant difference between TAVR and SAVR was found for the composite rate
of death from any cause, stroke, or MI after 1 year. (Nordic Aortic Valve Intervention Trial [NOTION]; NCT01057173)
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2185AB BR E V I A T I O N S
AND ACRONYM S
AF = atrial ﬁbrillation
AKI = acute kidney injury
CAD = coronary artery disease
CT = computed tomography
2DE = 2-dimensional
transesophageal
echocardiography
EuroSCORE = European
System for Cardiac Operative
Risk Evaluation
MI = myocardial infarction
NYHA = New York Heart
AssociationA ortic valve stenosis is the most prevalentheart valve disease in the Western world,and it has a poor prognosis after symptom
onset (1–3). Previously, surgical aortic valve replace-
ment (SAVR) was the only effective treatment, but af-
ter being introduced in 2002, transcatheter aortic
valve replacement (TAVR) became an option for
certain patients with severe symptomatic aortic valve
stenosis that was considered inoperable or in patients
at high risk for surgical complications (4,5). More
recently, observational studies have demonstrated
acceptable mortality outcomes in low- and
intermediate-risk patients (6–10); however, no ran-
domized clinical trials have been conducted in this
patient population.SEE PAGE 2195
SAVR = surgical aortic valve
replacement
STS-PROM = Society of
Thoracic Surgeons Predicted
Risk Of Mortality
TAVR = transcatheter aortic
valve replacement
TIA = transient ischemic attackDifferent TAVR systems have been developed, and
currently self-expandable or balloon-expandable
bioprostheses are used. Patients undergoing TAVR
and SAVR procedures experience different spectra
of complications related to the different nature of
the treatments. After TAVR, more patients have
prosthesis regurgitation, conduction disturbances
requiring a pacemaker, and vascular complications,
whereas SAVR-treated patients have more bleeding,
acute kidney injury (AKI), and new-onset atrial
ﬁbrillation (AF) (11,12). The impact of these compli-
cations on mortality and morbidity has not been
ﬁrmly established. In high-risk patients, improved
survival was demonstrated with TAVR using a self-
expanding prosthesis compared with SAVR after
1 year (12), whereas survival was similar to ﬁndings
with SAVR after 1 and 2 years when a balloon-
expandable prosthesis was used (11,13).
The NOTION (Nordic Aortic Valve Intervention)
trial is an all-comers trial evaluating the beneﬁts and
harms of TAVR using a self-expanding prosthesis
versus SAVR in patients with echocardiographically
severe aortic valve stenosis.
METHODS
The NOTION trial was an investigator-initiated,
multicenter, randomized, nonblinded, superiority
trial conducted at 2 centers in Denmark and 1 in
Sweden. The trial design has been described in detail
previously (14). A total of 280 patients were randomly
assigned to TAVR using a self-expanding prosthesis
versus SAVR and were followed for 5 years. The pri-
mary outcome was evaluated after 1 year.
The regional ethical review board at each site
approved the trial protocol, and the trial was con-
ducted according to the principles of the Declaration
of Helsinki. All patients provided written informedconsent. The investigators collected and
stored all data, which were fully monitored
by an independent monitoring unit. An in-
dependent clinical events committee adjudi-
cated all clinical events. An independent
statistician conﬁrmed the statistical analysis.
All authors conﬁrm that the trial was con-
ducted according to the protocol, and they
vouch for the accuracy and completeness of
the data and analyses.
PATIENT SELECTION. Patients $70 years of
age with severe degenerative aortic valve
stenosis referred for SAVR and also candi-
dates for TAVR were eligible for inclusion
regardless of their predicted risk of death af-
ter surgery. A heart team consisting of at least
an imaging cardiologist, an interventional
cardiologist, and a cardiac surgeon evaluated
all patients. Severe aortic valve stenosis was
deﬁned as an effective oriﬁce area <1 cm2 or
indexed for body surface area <0.6 cm2/m2
and a mean aortic valve gradient >40 mm Hg
or peak systolic velocity >4 m/s. Symptomatic pa-
tients had to have dyspnea, New York Heart Associ-
ation (NYHA) functional class II or higher, angina
pectoris, or cardiac syncope to qualify for the trial.
Asymptomatic patients could be included if they had
left ventricular posterior wall thickness $17 mm,
decreasing left ventricular ejection fraction, or new-
onset AF. Eligible patients were expected to survive
for more than 1 year. Patients were excluded if they
had another severe heart valve disease or coronary
artery disease (CAD) requiring intervention. Other
important exclusion criteria were previous cardiac
surgery, myocardial infarction (MI) or stroke within
30 days, severe renal failure requiring dialysis, or
pulmonary failure with a forced expiratory volume
within 1 s or diffusion capacity <40% of expected.
Trial eligibility, choice of prosthesis size, and
arterial access route were based on transthoracic and
transesophageal echocardiograms and an aorto-ilio-
femoral angiogram and were conﬁrmed by the pri-
mary interventional and surgical investigator at each
site. Supplemental computed tomography (CT)
studies were performed in patients with difﬁcult
aortic annular measurements or peripheral arterial
disease.
PROCEDURES. Patients were randomized in a 1:1 ra-
tio to treatment with TAVR or SAVR. Randomization
was performed at the Copenhagen Trial Unit and was
stratiﬁed according to trial site, age (70 to 74 years or
older), and history of CAD (yes or no). The allocation
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2186sequence was arranged in permuted blocks, and block
size was unknown to the investigators.
Patients randomized to TAVR received the Core-
Valve self-expanding bioprosthesis (Medtronic Inc.,
Minneapolis, Minnesota) in sizes 23, 26, 29, or 31 mm.
The preferred route of arterial access was femoral,
with left subclavian access as the second choice. The
procedure was performed using general or local
anesthesia, as described previously (15). Patients
received a loading dose of pre-procedural clopidogrel
(300 mg) and aspirin (75 mg) and unfractionatedFIGURE 1 Patient Flow
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TABLE 1 Baseline Characteristics
TAVR*
(n ¼ 145)
SAVR*
(n ¼ 135)
Age, yrs 79.2  4.9 79.0  4.7
Male 78/145 (53.8) 71/135 (52.6)
NYHA functional classiﬁcation
I 7/144 (4.9) 3/134 (2.2)
II 67/144 (46.5) 70/134 (52.2)
III 67/144 (46.5) 57/134 (42.5)
IV 3/144 (2.1) 4/134 (3.0)
STS-PROM score, % 2.9  1.6 3.1  1.7
Logistic EuroSCORE, % 8.4  4.0 8.9  5.5
Logistic EuroSCORE II, % 1.9  1.2 2.0  1.3
Additive EuroSCORE, % 7.4  1.4 7.5  1.4
Diabetes mellitus 26/145 (17.9) 28/135 (20.7)
Creatinine level >2 mg/dl 2/145 (1.4) 1/135 (0.7)
History of hypertension 103/145 (71.0) 103/135 (76.3)
Peripheral vascular disease 6/145 (4.1) 9/135(6.7)
Prior cerebrovascular accident 24/145 (16.6) 22/135 (16.3)
Chronic lung disease 17/145 (11.7) 16/135 (11.9)
Cardiac risk factors
Prior PCI 11/145 (7.6) 12/135 (8.9)
Pre-existing pacemaker 5/145 (3.4) 6/135 (4.4)
Prior MI 8/145 (5.5) 6/135 (4.4)
Prior AF/atrial ﬂutter 40/144 (27.8) 34/133 (25.6)
Values are mean  SD or n/N (%). *No statistical signiﬁcant differences between
groups were found for any variable.
AF ¼ atrial ﬁbrillation; EuroSCORE ¼ European System for Cardiac Operative
Risk Evaluation; MI ¼ myocardial infarction; NYHA ¼ New York Heart Association;
PCI ¼ percutaneous coronary intervention; SAVR ¼ surgical aortic valve replace-
ment; STS-PROM ¼ Society of Thoracic Surgeons Predicted Risk Of Mortality;
TAVR ¼ transcatheter aortic valve replacement.
TABLE 2 Procedural Characteristics
TAVR
Procedural success* 139/142 (97.9)
Total procedure time, min 90.3  38.6
Local anesthesia 26/142 (18.3)
Use of inotropes 86/142 (60.6)
Implantation of >1 valve prosthesis 4/142 (2.8)
Conversion to surgery 3/142 (2.1)
Transfemoral access 137/142 (96.5)
Transsubclavian access 5/142 (3.5)
Valve size implanted
23 mm 2/142 (1.4)
26 mm 57/142 (40.1)
29 mm 69/142 (48.6)
31 mm 14/142 (9.9)
SAVR
Total procedure time, min 177.2  39.8
Conversion to other procedure† 2/134 (1.5)
Use of inotropes 48/133 (36.1)
Valve size implanted
19 mm 11/132 (8.3)
21 mm 42/132 (31.8)
23 mm 45/132 (34.1)
25 mm 32/132 (24.2)
27 mm 2/132 (1.5)
Values are n/N (%) or mean  SD. *Deﬁned as leaving the catheterization room
with a functional transcatheter self-expanding prosthesis. †1 apico-aortic conduit
and 1 apical TAVR with a balloon-expandable bioprosthesis.
Abbreviations as in Table 1.
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2187postoperative antiplatelet and anticoagulation
regimen similar to that used for the TAVR-treated
patients. All patients received prophylactic antibi-
otics during the procedure, and senior interventional
cardiologists or cardiac surgeons performed all
procedures.
Follow-up assessments, including a physical ex-
amination, documentation of trial-speciﬁed outcomes
and adverse events, NYHA functional classiﬁcation,
blood sampling, and 12-lead electrocardiography,
were done before discharge and 1, 3, and 12 months
after the procedure. Specially trained echocardio-
graphic technicians performed transthoracic echocar-
diograms at baseline and after 3 and 12 months.
Experienced cardiologists evaluated all echocardio-
grams. National electronic medical records conﬁrmed
all clinical outcomes. When a neurological lesion was
suspected, an independent neurologist conducted a
formal neurological examination, and cerebral imag-
ing studies were performed.
OUTCOMES. The primary outcome was the compos-
ite rate of all-cause death, stroke, or MI 1 yearpost-procedure. Exploratory outcomes were as fol-
lows: the rate of individual components of the com-
posite outcome; the rate of cardiovascular death;
prosthesis reintervention; cardiogenic shock; valve
endocarditis; conduction abnormalities requiring
permanent pacemaker; atrial ﬁbrillation or ﬂutter;
and vascular, renal, and bleeding complications after
1 and 12 months. Clinical improvement was assessed
according to NYHA functional classiﬁcation. Echo-
cardiographic outcomes included aortic valve effec-
tive oriﬁce area, mean pressure gradient, and degree
of total aortic valve regurgitation (graded as none/
trace, mild, moderate, and severe) at 3 and 12 months.
All outcomes were deﬁned according to Valve Aca-
demic Research Consortium-2 deﬁnitions (16).
STATISTICAL ANALYSIS. The primary hypothesis
was that the rate of the composite outcome of death
from any cause, stroke, or MI after 1 year would be
lower for patients receiving TAVR versus SAVR. On
the basis of available clinical data (17), in-hospital
procedure databases, and predicted operative mor-
tality risk (EuroSCORE I [European System for Cardiac
Operative Risk Evaluation version I]), we assumed an
estimated occurrence of the primary outcome of 5%
after TAVR and 15% after SAVR. With a 1:1 ratio in the
CENTRAL ILLUSTRATION TAVR Versus SAVR in Severe Aortic Valve Stenosis
Thyregod, H.G.H. et al. J Am Coll Cardiol. 2015; 65(20):2184–94.
An all-comers patient population with severe aortic valve stenosis was randomized 1:1 to transcatheter aortic valve replacement (TAVR) or surgical aortic
valve replacement (SAVR). The primary outcome was the composite rate of death from any cause, stroke, or myocardial infarction at 1 year, and there were
no signiﬁcant difference in the primary outcome between the 2 groups or in its components, including all-cause mortality (top) and stroke (bottom).
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TABLE 3 Clinical Outcomes in the As-Treated Population
Index Hospitalization*
or 30 Days† 1 Year
TAVR SAVR p Value TAVR SAVR p Value
Major, life threatening, or
disabling bleeding*
16 (11.3) 28 (20.9) 0.03
Cardiogenic shock* 6 (4.2) 14 (10.4) 0.05
Major vascular complications* 8 (5.6) 2 (1.5) 0.10
Acute kidney injury stage II or III* 1 (0.7) 9 (6.7) 0.01
All-cause death† 3 (2.1) 5 (3.7) 0.43 7 (4.9) 10 (7.5) 0.38
Cardiovascular death† 3 (2.1) 5 (3.7) 0.43 6 (4.3) 10 (7.5) 0.25
Neurological events† 4 (2.8) 4 (3.0) 0.94 7 (5.0) 8 (6.2) 0.68
Stroke† 2 (1.4) 4 (3.0) 0.37 4 (2.9) 6 (4.6) 0.44
Transient ischemic attack† 2 (1.4) 0 (0) 0.17 3 (2.1) 2 (1.6) 0.71
MI† 4 (2.8) 8 (6.0) 0.20 5 (3.5) 8 (6.0) 0.33
Valve endocarditis† 1 (0.7) 0 (0) 0.33 4 (2.9) 2 (1.6) 0.47
New-onset or worsening AF† 24 (16.9) 77 (57.8) <0.001 30 (21.2) 79 (59.4) <0.001
Permanent pacemaker
implantation†
46 (34.1) 2 (1.6) <0.001 51 (38.0) 3 (2.4) <0.001
Values are n (%). *Rate during index hospitalization; data reported as number of patients with events
(percentage) in each treatment group; p values were calculated by Fisher exact test or chi-square test, as
appropriate. †Rates determined at 30 days and 1 year; data reported as number of subjects (Kaplan-Meier
estimates) at the speciﬁc time point, and they do not equal the number of patients with events divided by the
total number of patients in each treatment group; p values were calculated by the log-rank test for all data
through 30 days or 1 year.
Abbreviations as in Table 1.
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2189treatment assignment, we calculated that 140 pa-
tients in each group would be required to have 80%
power at a 2-sided alpha-level of 5%.
The analysis for the primary outcome was per-
formed in the intention-to-treat population with lo-
gistic regression by adjusting for age, trial site, and
history of CAD with a 2-sided alpha level of 5%. The
primary outcome was also analyzed in the as-treated
population. The intention-to-treat population was
deﬁned as all patients randomized, the as-treated
population as patients in whom 1 of the 2 trial pro-
cedures was attempted. All outcomes, apart from the
primary outcome, were considered exploratory.
A time-to-event analysis was conducted using
Kaplan-Meier estimates, and comparisons between
treatment groups were done using the log-rank test.
Categorical variables were compared using the Fisher
exact test or the chi-square test as appropriate.
Continuous variables were presented as means ( SD)
and compared with the use of Student t test. Ordinal
variables were compared using the Mantel-Haenszel
test. All testing used a 2-sided alpha level of 0.05.
All statistical analyses were performed with the use of
SAS software version 9.2 (SAS Institute, Cary, North
Carolina).
RESULTS
From December 2009 to April 2013, 1,576 patients
were evaluated by the Heart Team at participating
centers and were pre-screened for trial participation.
A total of 1,296 patients were excluded: 79% did not
meet inclusion criteria; 8% declined to participate; 1%
withdrew informed consent (3 in the transcatheter
group and 5 in the surgical group); and 12% were
excluded for other reasons. The remaining 280 pa-
tients were randomized (145 TAVR and 135 SAVR, the
intention-to-treat population). A procedure was
attempted in 276 patients (142 TAVR and 134 SAVR,
the as-treated population) (Figure 1). Four patients
died before the procedure (3 TAVR and 1 SAVR), and 2
patients (1 in each group) were crossed over to the
other procedure before an attempted procedure. The
patient crossing from SAVR to TAVR died 11 days
post-procedure.
Table 1 describes the baseline characteristics of the
intention-to-treat population. The 2 groups were well
balanced, with a mean age of 79.1  4.8 years, 53.2%
male sex, and 47.1% in NYHA functional class III or IV.
The comorbidity burden was moderate, with 19.3%
having diabetes mellitus, 16.4% prior cerebrovascular
disease, and 11.8% chronic obstructive pulmonary
disease. Only 5.4% had peripheral vascular disease.
When calculating the Society of Thoracic SurgeonsPredicted Risk Of Mortality (STS-PROM) and Euro-
SCORE I and II estimates for 30-day predicted surgical
mortality risk, 81.8% were considered low-risk pa-
tients (STS-PROM <4, mean  SD, 3.0  1.7), and
mean logistic EuroSCORE I and II values were 8.6 and
2.0, respectively.
In the as-treated population, mean time from
randomization to procedure was 32.5 days for TAVR
and 40.9 days for SAVR (p ¼ 0.08). Two patients
assigned to SAVR were not treated with a trial pro-
cedure (1 treated with an apico-aortic conduit and 1
with apical TAVR using a balloon-expandable bio-
prosthesis); 3 TAVR-treated patients were converted
to SAVR because of complications during the proce-
dure. A total of 139 and 135 patients had the trial
TAVR and SAVR prosthesis implanted, respectively.
The arterial access was femoral in 96.5% of TAVR-
treated patients (Table 2). No patients were lost to
follow-up.
OUTCOMES. In the intention-to-treat analysis, the
composite rate of death from any cause, stroke, orMI at
1 year (the primary outcome) was similar in the
2 groups (13.1% vs. 16.3% for TAVR and SAVR,
respectively; 3.2% absolute difference; p ¼ 0.43 for
superiority). The result did not change in the
as-treated analysis (11.3% vs. 15.7%; 4.4 absolute
difference; p ¼ 0.30). The composite outcome was
primarily driven by death from any cause (Kaplan-
Meier rate 4.9%vs. 7.5%; p¼0.38) (Central Illustration).
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Symptomatic status varied according to New York Heart Association (NYHA) class at baseline, after 3 months, and after 1 year in patients with
an attempted procedure. At 1 year, the transcatheter aortic valve replacement group had signiﬁcantly more dyspnea versus the surgical group
(p ¼ 0.01).
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with surgical patients had lower rates of major or life-
threatening bleeding (11.3% vs. 20.9%; p ¼ 0.03),
cardiogenic shock (4.2% vs. 10.4%; p ¼ 0.05), and AKI
(stage II or III) (0.7% vs. 6.7%; p ¼ 0.01) (Table 3). No
TAVR-treated patient required percutaneous coro-
nary intervention during the procedure, but 2 such
patients had cardiac perforation; 1 SAVR-treated pa-
tient required concomitant coronary artery bypass
resulting from a right coronary ostium lesion. The
mean in-hospital time after the index procedure was
shorter for TAVR (8.9  6.2 days vs. 12.9  11.6 days;
p ¼ 0.001). No difference was found for major
vascular complications.
At 30 days in the as-treated population, more
TAVR-treated patients had conduction abnormalities
requiring a permanent pacemaker (34.1% vs. 1.6%;
p < 0.001), but they had a lower rate of new-onset or
worsening AF (16.9% vs. 57.8%; p < 0.001). There was
no signiﬁcant difference between treatment groups
in the composite outcome or any of its separate
components. In addition, no difference was found in
the rate of cardiovascular death or transient is-
chemic attack (TIA). No patient had prosthesis
reintervention.
The rates of death from any cause, cardiovascular
death, stroke or TIA, or MI did not differ between
treatment groups at 1 year (see Table 3), nor did any
patient have signiﬁcant prosthesis dysfunction
requiring intervention after 1 year.The rate of permanent pacemaker implantation
remained higher in TAVR-treated patients (38.0% vs.
2.4% for TAVR and SAVR; p < 0.001) at 1 year,
whereas the rate of new-onset or worsening AF was
lower (21.2% vs. 59.4%; p < 0.001) compared with
SAVR-treated patients. The number of cardiopul-
monary, neurology, vascular, or bleeding-related
hospitalizations or the number of days hospitalized
during the ﬁrst year was not different between
treatment groups within the ﬁrst year.
FUNCTIONAL OUTCOMES. Patients in both treat-
ment groups experienced signiﬁcant improvement in
dyspnea as measured by NYHA functional class by
30 days, and this improvement was maintained at
1 year (Figure 2). After 1 year, TAVR-treated patients
had more dyspnea compared with SAVR-treated pa-
tients (29.5% in NYHA functional class II indicating
mild dyspnea vs. 15.0%; p ¼ 0.01).
The effective oriﬁce area improved after both
procedures and remained constant at 1 year
(Figure 3). Compared with SAVR-treated patients,
TAVR-treated patients had more improvement in
effective oriﬁce area relative to baseline at 3 months
and 1 year (change from baseline to 1 year: 1.0 
0.5 cm2 vs. 0.6  0.5 cm2; p < 0.001). The mean
pressure gradient decreased as a result of each
procedure, although this change did not differ be-
tween groups at 1 year (change from baseline to
1 year: 34.8  18.0 mm Hg vs. 32.0  18.3 mm Hg;
p ¼ 0.23). TAVR-treated patients experienced a
FIGURE 3 Aortic Valve Hemodynamics
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Aortic valve hemodynamics were measured as mean effective oriﬁce area (in cm2) and
mean aortic valve gradient (in mm Hg) according to implanted valve prosthesis at baseline,
at 3 months, and at 1 year. The transcatheter aortic valve replacement group had signiﬁ-
cantly greater improvement in effective oriﬁce area versus the surgical group at each time
point (p < 0.001).
FIGURE 4 Total Aortic Valve Regurgitation
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Although improved at 1 year from 3 months, the transcatheter aortic valve replacement
group had signiﬁcantly more regurgitation versus the surgical group at each time point
(p < 0.001).
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tation compared with SAVR-treated patients at 3
months, and this rate remained stable during the
ﬁrst year (for moderate to severe regurgitation at
1 year: 15.7% vs. 0.9%; p < 0.001) (Figure 4).
DISCUSSION
The NOTION trial is a randomized all-comers popu-
lation with varying degrees of clinical symptoms and
echocardiographically severe aortic valve stenosis to
TAVR versus SAVR. Although TAVR was not superior
to SAVR for the primary outcome, which was the
composite rate of death from any cause, stroke, or MI
after 1 year, the trial showed that TAVR appeared safe
and effective in low- and intermediate-risk patients.
There were no differences between treatment groups
at any time point for any individual component of the
composite outcome or for cardiovascular death, TIA,
or prosthesis reintervention.
The results concur with propensity score-matched
studies, showing no differences in death from any
cause between TAVR and SAVR after 30 days or 1 year
for patients with an STS-PROM score #4% (8) or in
patients with a mean logistic EuroSCORE I of 9.1%
after 30 days (9). In an exploratory post-hoc analysis in
the current trial, noninferiority could be shown for
TAVR compared with SAVR for the primary outcome
when using the same noninferiority margin of 7.5%
used in the PARTNER (Placement of Aortic Trans-
catheter Valves) and U.S. CoreValve High Risk trials
(11,12).
The NOTION trial was designed to compare TAVR
with standard surgical treatment in patients most
often referred for treatment in contemporary clinical
practice. At the time of trial design, there were no
randomized TAVR trials or observational studies
including low- and intermediate-risk patients. It was
expected that the lower-risk patients would show
greater beneﬁt from the less invasive TAVR procedure
than their higher-risk counterparts; however, the
magnitude of this beneﬁt was uncertain.
For the surgical group, the mean 30-day risk of
mortality in NOTION was estimated to be 3.1% using
the STS-PROM score and 8.6% and 2.0% using the lo-
gistic EuroSCORE I and EuroSCORE II, whereas
the observed 30-day mortality rate was 3.7%. The
NOTION patient population was therefore different
from those in the 2 other randomized trials comparing
TAVR and SAVR. In the PARTNER trial, using a balloon-
expandable prosthesis, the mean STS-PROMwas 11.7%
for the surgical group (11) versus 7.5% in the surgical
group of the U.S. CoreValve High Risk trial using the
same self-expanding prosthesis as in NOTION trial (12).The actual mortality at 30 days was 8.0% and 4.5% in
those 2 trials, respectively.We found better agreement
in particular between the STS-PROM estimate and
observed 30-day mortality compared with other
studies with high-risk patients (18,19). In an observa-
tional study of TAVR in low-risk patients (STS-PROM
score <4%), the mortality rates at 30 days and 1 year
were similar to ours (10).
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was one of the lowest ever reported for transcatheter
therapy, and stroke rates after both treatments were
also low compared with any previously reported
series. In particular, TAVR-treated patients did not
have a higher rate of neurological events, which has
been a concern related to catheter manipulation of the
calciﬁed aorta and balloon valvuloplasty (20). Aortic
valve regurgitation was more prevalent in TAVR-
treated patients (15.7% had moderate or severe
regurgitation after 1 year) and did not improve over
time. This prevalence was higher than seen in the U.S.
CoreValve High Risk trial (6.1% at 1 year) (12), but it
was similar to other observational studies also using a
self-expanding prosthesis (21,22). Both mild (13) and
moderate-severe aortic valve regurgitation have been
associated with increased mortality after TAVR
(21,22). This difference in aortic valve regurgitation
may partly explain the difference seen in NYHA
functional class at 1 year, with more TAVR-treated
patients experiencing mild dyspnea. However, no
difference between groups could be demonstrated
in the rate of death or hospitalization during the
ﬁrst year.
The inherent differences between TAVR and
SAVR, with regard to procedures and valve de-
signs, were seen in the procedure-related outcomes.
TAVR-treated patients had more conduction abnor-
malities requiring a permanent pacemaker and minor
vascular complications, whereas SAVR-treated pa-
tients had more bleeding complications, cardiogenic
shock, AKI, and new-onset or worsening AF, and they
also had a longer post-procedure hospital stay. Well
documented in other trials (11,12), these differences
reﬂect the less invasive nature of transcatheter
treatment.
The NOTION trial was initiated only 2 years after
TAVR was widely introduced, and experience with
the procedure was limited. Furthermore, because this
trial was designed in 2009, numerous improvements
to the TAVR procedure were subsequently intro-
duced. At the time when patients were enrolled in
the NOTION trial, 2-dimensional transesophageal
echocardiography (2DE) was the standard of care for
annular sizing, whereas the U.S. CoreValve High Risk
trial relied on CT for sizing (12). Since that time, 2DE
has been shown to cause systematic valve undersiz-
ing and aortic valve regurgitation compared with CT
(23–25). Moreover, using CT studies to measure the
distance from annulus to coronary ostia and the de-
gree of valvular and access vessel calciﬁcation may
potentially reduce the risk of coronary artery
obstruction, aortic annulus rupture, stroke, conduc-
tion abnormalities, and vascular complications (26).We found no signs of prosthesis deterioration dur-
ing the ﬁrst year, and no patient had prosthesis rein-
tervention. Favorable long-term durability data (up to
3 and 6 years) for TAVR prostheses are emerging
(27,28), but more randomized long-term data are
needed. In addition, the clinical signiﬁcance of aortic
valve regurgitation and ventricular pacing on
morbidity and mortality must be better understood, or
these complications must be avoided in newer gener-
ations of transcatheter valves, before broadening the
indications for TAVR in lower-risk patients.
STUDY LIMITATIONS. The NOTION trial used cen-
tralized randomization stratiﬁed for relevant prog-
nostic factors (29,30). The trial methodologies have
been described in detail, including the plans for sta-
tistical analyses (14). Moreover, 2 independent teams
analyzed and validated the results.
Several outcomes were assessed unblinded as to
procedure; accordingly, assessments of all outcomes
apart from death could be subject to bias (29,30). It is,
however, difﬁcult to know the direction of such bias.
Our sample size may have been too small to detect a
potential difference in treatment effect on the pri-
mary outcome. Because experience with TAVR was
limited when NOTION was initiated, most operators
were comfortable using only a single TAVR system.
Differences between self-expanding and balloon-
expandable valves with regard to aortic valve regur-
gitation and pacemaker requirement, for example,
have been well described (31). External validity was
limited in our trial because only 3 centers recruited
patients. The current trial results may therefore not
be extrapolated to TAVR in general. The NOTION trial
did not recruit patients with signiﬁcant concomitant
CAD, and outcomes for this large patient population
cannot necessarily be inferred from the current trial.
Formal neurological assessments were not performed
in all patients, and more subtle neurological symp-
toms (e.g., cognitive dysfunction) could have been
overlooked. The difﬁculties in determining the de-
gree of aortic valve regurgitation after replacement
are well known, and independent echocardiographic
evaluations were not made.
CONCLUSIONS
The NOTION trial was an all-comers trial in patients
with aortic valve stenosis who were randomized to
transcatheter versus surgical aortic valve replace-
ment. No signiﬁcant differences were found between
the 2 procedures regarding the primary outcome
death from any cause, stroke, or MI or the exploratory
outcomes of cardiovascular mortality or prosthesis
reintervention after 1 year. The transcatheter group
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: In a randomized
comparison of TAVR versus SAVR, TAVR was associated with
more frequent requirement for pacemaker implantation, larger
improvement in effective valve oriﬁce, more aortic valve regur-
gitation, and more residual exertional dyspnea at 1 year, whereas
SAVR was more often associated with major or life-threatening
bleeding, cardiogenic shock, acute kidney injury, and early post-
procedural AF.
TRANSLATIONAL OUTLOOK: Further studies are needed to
compare the safety, efﬁcacy, and long-term clinical outcomes of
TAVR versus SAVR in lower-risk patients with severe aortic valve
stenosis.
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2193did signiﬁcantly better than the surgical group
regarding rates of bleeding, cardiogenic shock, AKI,
new-onset or worsening AF, effective oriﬁce area, and
number of days hospitalized. The surgical group
appeared signiﬁcantly better in terms of conduction
abnormalities requiring a permanent pacemaker,
NYHA functional class at 1 year, and aortic valve
regurgitation. Therefore, at present we are not able to
recommend or refute 1 procedure over the other in
lower-risk patients. More randomized clinical trials in
this patient population are needed.
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